Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Uterine Leiomyosarcoma
NCT00101127Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Dec 2003
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in uterine leiomyosarcoma (uLMS), sponsored by GOG Foundation. Primary endpoints: Antitumor Activity and Toxicity. Started Dec 2003; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT00101127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101127.